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Abstract
Background: The P-glycoprotein, encoded by the ABCB1 gene, is expressed in human endothelial and mesangial cells,
which contribute to control renal plasma flow and glomerular filtration rate. We investigated the association of ABCB1
variants with renal function in African and Caucasian subjects.
Methods: In Africans (290 subjects from 62 pedigrees), we genotyped the 2677G>T and 3435 C>T ABCB1
polymorphisms. Glomerular filtration rate (GFR) was measured using inulin clearance and effective renal plasma flow
(ERPF) using para-aminohippurate clearance. In Caucasians (5382 unrelated subjects), we analyzed 30 SNPs located
within and around ABCB1, using data from the Affymetrix 500 K chip. GFR was estimated using the simplified Modification
of the Diet in Renal Disease (MDRD) and Cockcroft-Gault equations.
Results: In Africans, compared to the reference genotype (GG or CC), each copy of the 2677T and 3435T allele was
associated, respectively, with: GFR higher by 10.6 ± 2.9 (P < 0.001) and 4.4 ± 2.3 (P = 0.06) mL/min; ERPF higher by 47.5
± 11.6 (P < 0.001) and 28.1 ± 10.5 (P = 0.007) mL/min; and renal resistances lower by 0.016 ± 0.004 (P < 0.001) and 0.011
± 0.004 (P = 0.004) mm Hg/mL/min. In Caucasians, we identified 3 polymorphisms in the ABCB1 gene that were strongly
associated with all estimates of GFR (smallest P value = 0.0006, overall P = 0.014 after multiple testing correction).
Conclusion: Variants of the ABCB1 gene were associated with renal function in both Africans and Caucasians and may
therefore confer susceptibility to nephropathy in humans. If confirmed in other studies, these results point toward a new
candidate gene for nephropathy in humans.
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A better knowledge of the determinants of renal function
is of paramount importance considering the high and
increasing burden of chronic kidney disease worldwide.
[1] The familial aggregation of renal function [2-4] sug-
gests that genetic factors determine, in part, renal function
and that there are candidate genes for nephropathy in
humans.
The transmembrane efflux-P-glycoprotein (PGP; also
known as multidrug resistance-associated protein 1) is
encoded by the ABCB1 gene, several genetic variants of
which have been shown to influence PGP expression in
humans. PGP has been extensively studied in a pharmaco-
genetic context, in particular for its role in multi-drug
resistance in cancer treatment. PGP is widely expressed in
the human kidney [5-7] and is involved in ciclosporin-
induced post-transplantation nephrotoxicity [5,8,9], pos-
sibly because of its influence on ciclosporin absorption.
[10]ABCB1 genetic variants have been associated with
post-transplantation ciclosporin-induced nephrotoxicity.
[10-12] In contrast to the extensive data about the physi-
ological role of PGP on the transport of xenobiotics, little
is known about the role of PGP in the transport of endog-
enous substrates and to our knowledge, ABCB1 gene vari-
ants have not been previously associated with renal
function in the absence of xenobiotics in humans. [13]
Since PGP is expressed in human endothelial and
mesangial cells, which contribute to the control of renal
plasma flow and glomerular filtration, we hypothesized
that variants in the ABCB1 gene could be associated with
renal hemodynamics and glomerular filtration rate
(GFR), even in the absence of treatment by PGP substrates
and/or modulators, such as ciclosporin. In particular, we
investigated whether the 3435 C>T and the 2677G>T
ABCB1 variants are associated with GFR, effective renal
plasma flow (ERPF) and renal vascular resistance (RVR) in
families of African descent. We then confirmed an associ-
ation of variants in the ABCB1 gene with renal function
using the 30 genetic markers located within the ABCB1
gene in a large ongoing population-based genome-wide
association study of Caucasians employing the Affymetrix
500 K chip.
Methods
Seychelles study
Study population
In the Seychelles islands (Indian Ocean, African region),
we enrolled 494 subjects of East African descent from 76
families enriched in hypertensive individuals between
August 1999 and January 2002. The detailed family selec-
tion process has been previously described. [2] Renal
hemodynamics and ABCB1 genotype were determined in
297 individuals. We excluded seven individuals with
extreme outlier values for any of the renal measures, i.e.
observations lying beyond three interquartile ranges from
the first and third quartiles, leaving 290 individuals to
analyze the associations of interest. The study was
approved by the Ethical Committees of the Ministry of
Health in the Seychelles and of the University of Lausanne
(Switzerland). All participants provided written informed
consent.
Phenotype and covariate measurements
In the Seychelles study, antihypertensive therapy, if any,
was stopped for 2 weeks before clearance protocols. After
a two-hour equilibration period, two one-hour inulin and
PAH clearances were obtained to measure GFR and ERPF,
respectively [see Additional file 1]. The inulin and PAH
clearances (Cx) were calculated with the formula Cx =
Ux*V/Px, where Ux and Px are urinary and plasma concen-
trations of the x solute, and V is the urine flow rate in ml/
min. Renal blood flow (RBF) was calculated as ERPF/(1-
(haematocrit/100)) and RVR as (mean arterial blood pres-
sure)/RBF. GFR was also estimated using the abbreviated
Modification of the Diet in Renal Disease (MDRD) equa-
tion [14]. Creatinine concentration was measured by the
picric acid method (Cobas-Mira, Roche, Basel, Switzer-
land). Mean arterial blood pressure (MAP) was calculated
as diastolic blood pressure plus 1/3 of (systolic minus
diastolic blood pressure) from the mean of 6 measure-
ments taken with a mercury sphygmomanometer (3 on
the day preceding clearances and 3 on the morning of the
clearances). On the day preceding clearance, participants
collected urine for 24 hours. Urinary and plasma sodium
and potassium concentrations were measured by flame
photometry (IL-943, Instrumentation Laboratory, Milan,
Italy). Participants on antidiabetic treatment during the
preceding month, or with fasting blood glucose ≥ 7.0
mmol/l (measured on venous whole blood in duplicate
using a Glycotronic® C reflectometer, Macherey-Nagel,
Düren, Germany), were considered as diabetics. Body sur-
face area was calculated using the Dubois formula. [15]
Body mass index (BMI) was calculated as weight (kg)
divided by squared height (m2).
Genetic analyses
DNA was isolated using standard methods from blood
drawn into K-EDTA tubes and stored at 4°C. The ABCB1
genotypes (exon 21, 2677 G>T [rs2032582] and exon 26,
3435 C>T [rs1045642]) were determined by real-time
PCR with TaqMan®, as previously described. [16,17] The
marker genotypes did not significantly deviate from
Hardy-Weinberg proportions (P > 0.09) in founders, and
2677 G>T and 3435 C>T were in strong linkage disequilib-
rium (D' = 0.90) with each other.Page 2 of 11
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We used the ASSOC program in S.A.G.E. (V5.3) [18],
which accounts for familial correlations by implementing
simultaneous maximum likelihood estimation of both
familial components of variance and covariate coeffi-
cients, to conduct linear regressions with GFR, ERPF or
RVR as dependent variables. Based on the findings from
descriptive analyses in our sample (i.e. GT heterozygotes
had phenotypic values lying between those of the GG and
TT homozygotes), we assumed an additive mode of action
for the ABCB1 3435T and 2677T alleles. To conduct anal-
yses stratified by hypertension status, we defined hyper-
tensive subjects as those on antihypertensive treatment at
entry into the study or having, respectively, a systolic and/
or diastolic blood pressure = 140/90 mm Hg. For multiple
linear regression models, we used as predictors age, sex,
BMI, 24-hour urinary sodium and potassium excretion,
fasting blood glucose, diabetes and MAP. All multivaria-
ble models included ascertainment as previously
described. [19] We conducted sensitivity analyses that
included extreme outlier values. We formally tested
whether normotensive and hypertensive subjects had sim-
ilar results by including a test of hypertension status by
genotype interaction (i.e. a likelihood ratio test with 2
degrees of freedom) in multivariable models. To ensure
that any associations were not due to population stratifi-
cation: (1) because some subjects were of mixed descent,
we conducted a sensitivity analysis that included only
those subjects (78%) with known grand-parent's ethnicity
who reported having at least 3 grand-parents of African
descent (n = 153), and (2) we extended our analysis of
GFR by a separate analysis of 119 subjects from the same
families with missing inulin clearance but available
MDRD. We also conducted analyses based on haplotypes.
For the 61 doubly heterozygous participants (CT/GT)
with a potentially ambiguous phase, ABCB1 haplotypes
were inferred using the HAPLORE program that uses an
expectation-maximisation (EM) algorithm in pedigree
data. [20]
CoLaus study
Study population
A simple non-stratified random sample (n = 56,694) rep-
resenting 35% of the overall population of the city of
Lausanne (Switzerland) aged 35–75 years was drawn.
Inclusion criteria were: a) written informed consent; b)
aged 35–75 years; c) available examination and blood
sample and d) Caucasian descent. The study was
approved by the ethical committee of the Faculty of Med-
icine of Lausanne. Recruitment began in June 2003 and
ended in May 2006. Among those eligible, the participa-
tion rate was 41%. Of the 6188 participants, 781 were
excluded because of missing or low quality genotyping
data, genetic relatedness with other subjects, or missing
phenotyping data, leaving 5407 subjects for the present
analyses.
Phenotype and covariate measurements
Venous blood samples (50 mL) were drawn after an over-
night fast, and clinical chemistry assays were performed
by the CHUV Clinical Laboratory on fresh blood samples
on a Modular P apparatus (Roche Diagnostics, Switzer-
land) within 2 hours of blood collection. Serum creati-
nine was measured by the Jaffe kinetic compensated
method (2.9% – 0.7% maximum inter and intra-batch
CVs). GFR was estimated using the abbreviated MDRD
equation [14] and the Cockcroft-Gault (CG) formula
[21]. Body weight and height were measured with partici-
pants standing without shoes in light indoor clothes.
Smoking was defined as present if a participant reported
to be a current smoker at the time of examination, and
alcohol consumption as present for participants reporting
drinking alcohol at least once a day. Diabetes was defined
as being on current antidiabetic treatment or having fast-
ing plasma blood glucose ≥ 7 mmol/L.
Genetic analyses
Nuclear DNA was extracted from whole blood for whole
genome scan analysis. Genotyping was performed on
6014 participant samples, using the Affimetrix 500 K SNP
chip, as recommended by the manufacturer. Individuals
with less than 95% genotyping efficiency overall (or
<90% efficiency on either array, N = 399), and individuals
with possible gender inconsistencies (N = 5), were
removed. Duplicate samples, and first and second degree
relatives were identified by estimating genomic identity-
by-descent (i.b.d.) coefficients; the younger individual
from each such pair was removed (N = 200). A further 3
individuals had missing phenotype data, leaving 5407
individuals with complete data available for analysis.
Monomorphic SNPs (N = 4052), SNPs with less than 70%
genotyping efficiency (N = 157), and SNPs not in Hardy-
Weinberg proportions (N = 35417) were excluded from
analysis.
Statistical analyses
A more detailed description of the statistical analyses can
be viewed in the Additional file 1. We excluded individu-
als with outlier phenotypic values defined as values lying
more than 4 SD away from the mean (N = 25), leaving
5382 individuals for association tests. Phenotype data
were transformed and adjusted for covariates using R. [22]
We used age, height, weight and BMI as continuous cov-
ariates, and sex, alcohol consumption, smoking, diabetes,
antidiabetic or antihypertensive treatment, the presence
(or absence) of each of the major classes of antihyperten-
sive drugs (ACE-inhibitors, angiotensin receptor blockers,
beta-blockers, channel calcium blockers and diuretics)
and currently (i.e. during the last 6 months) taking anyPage 3 of 11
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regression. To confirm the association, we used only
directly genotyped SNPs first and imputed SNPs in further
exploratory analyses. Association tests were performed
using PLINK (v0.99s) [23], with an additive mode of
action.
Results
Seychelles Study
The allele frequency was 34.1% overall and 30.8% in
founders for 2677T, and 54.5% and 53.9%, respectively,
for 3435T. Participants' characteristics by genotypes and
allele carrier status are presented in Table 1. There was no
significant trend across genotypes. Carriers of the 3435T
allele had a higher BMI than non-carriers (28.8 ± 0.4 ver-
sus 27.3 ± 0.5 kg/m2; P = 0.02).
The 2677T allele was associated, in an additive manner,
with higher GFR (P = 0.003) and ERPF (P = 0.005) and
lower RVR (P = 0.001) (Figure 1). Results were similar,
although slightly less significant with the 3435T allele.
These results suggest that the T allele is a protective allele
with respect to renal function. We obtained similar results
for renal haemodynamic phenotypes adjusted for body
surface area (Table 2). It is therefore unlikely that the dif-
ference in BMI observed between 3435T carriers and non-
carriers represents a major confounding factor for these
associations.
Because PGP is responsible for the transport of many
drugs, we conducted analyses stratified by hypertension
status (Figure 2). As the association was similar in normo-
tensive subjects and hypertensive subjects, it is unlikely
that our results reflect a confounding effect of antihyper-
tensive drugs. The hypertension status by genotype inter-
action was not significant (P > 0.05) in multivariable
models, which confirms that the associations were similar
in normotensive and hypertensive subjects.
Table 3 presents regression coefficients of the 2677T and
the 3435T allele, respectively, for the association with the
renal haemodynamic phenotypes. Models adjusted for
only age and sex differed little (i.e. by less than 30 percent
of a standard error; P > 0.60) from complete multivariable
models, which suggests that the extra covariate adjust-
ment had little influence on the results. In multivariable
models, each copy of the 2677T allele was associated with
a 10.6 mL/min higher GFR, a 47.5 mL/min higher ERPF,
and a 0.016 lower RVR as compared to the GG reference
genotype (P < 0.0001). While the effect sizes of the 2677T
allele were about 10% of the trait values, those of the
3435T allele were smaller and less significant. These
results suggest that, even after accounting for major
known confounding factors, ABCB1 genetic variants were
associated with renal function in this large sample. The
results of sensitivity analyses including extreme outlier
values did not differ by more than 1 standard error from
the analyses conducted after excluding extreme outliers (P
> 0.40).
Analyses restricted to subjects with at least 3 grand-parents
of African descent showed results that were similar in
direction and significance level to those obtained in the
whole sample. There was also a trend toward a similar
association of GFR estimated using MDRD with the 2677T
(8.6 ± 5.8 P = 0.14) and the 3435T (10.1 ± 5.3, P = 0.058)
alleles in analysis of MDRD in the 119 subjects for whom
inulin clearance values were missing.
Haplotype analyses showed that each copy of the TT hap-
lotype was associated with an 11.6 ml/min higher GFR, a
50.7 mL/min higher ERPF, and a 0.017 mm Hg/mL/min
Table 1: Distribution of selected characteristics by genotypes for each ABCB1 variant in the Seychelles
2677 G>T 3435 C>T
GG GT TT CC CT TT
N 191 84 15 132 118 40
Age (years) 46.8 ± 12.2 46.2 ± 11.8 44.6 ± 12.5 46.0 ± 12.2 47.3 ± 11.5 45.8 ± 13.3
Proportion of women 0.57 ± 0.50 0.51 ± 0.50 0.47 ± 0.52 0.59 ± 0.49 0.51 ± 0.50 0.53 ± 0.51
BMIa (kg/m2) 28.0 ± 5.6 28.5 ± 5.0 26.8 ± 4.2 27.3 ± 5.2 29.0 ± 5.7 28.0 ± 4.9
MAPb (mm Hg) 101 ± 13 103 ± 14 98 ± 15 100 ± 14 103 ± 13 99 ± 14
FBGc (mmol/L) 4.6 ± 1.8 4.6 ± 1.7 4.5 ± 1.6 4.6 ± 1.6 4.7 ± 1.9 4.6 ± 1.5
Diabetes (prevalence) 0.08 ± 0.28 0.11 ± 0.31 0.07 ± 0.26 0.08 ± 0.27 0.09 ± 0.29 0.13 ± 0.33
Plasma Na (mmol/L) 140 ± 4 140 ± 4 139 ± 3 140 ± 4 140 ± 4 139 ± 3
Plasma K (mmol/L) 3.8 ± 0.3 3.7 ± 0.3 3.7 ± 0.4 3.7 ± 0.3 3.8 ± 0.3 3.7 ± 0.3
Urine Na (mmol/24 h) 106 ± 54 107 ± 56 104 ± 67 101 ± 54 108 ± 56 118 ± 57
Urine K (mmol/24 h) 44 ± 18 46 ± 18 35 ± 16 44 ± 17 45 ± 19 44 ± 17
Results presented are the mean ± s.d. For each variant, there was no significant trend across genotypes. aBMI: body mass index. bMAP: mean arterial 
pressure. cFBG: fasting blood glucose.Page 4 of 11
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These results suggest that most of the signal was carried by
the 2677T allele because the 3435T allele adds only 1 mL/
min GFR or 3 ml/min ERPF.
CoLaus study
The 2526 men and 2856 women analyzed were aged 53.4
± 10.7 years (mean ± SD), had mean 25.8 ± 4.5 kg/m2
BMI and 79.6 ± 14.6 μmol/L serum creatinine. The SNPs
measured in the Seychelles (rs1045642 [3435 C>T], geno-
typed in CoLaus, and rs2032582 [2677 G>T], which is
tagged by 3 genotyped SNPs at r2 > 0.9 and 2 further gen-
otyped SNPs at r2 > 0.5) did not show any association with
any estimate of GFR [see Additional file 2]. We did how-
ever find strong evidence of association between GFR and
other SNPs in ABCB1. Testing the 30 directly genotyped
SNPs within 10 kb of ABCB1, and using square-root trans-
formed MDRD, we obtained P values of 0.0006, 0.0007,
0.0071, 0.0079 and 0.0085 for the five most significant
SNPs, using 105 permutations. All other SNPs had P val-
ues > 0.01 [see Additional file 2]. The overall permutation
P value for the most significant SNP, corrected for multi-
ple testing, was P = 0.014. We take this as positive evi-
dence for association.
The significance levels achieved here were sensitive to the
removal of 25 outlying individuals (using a 4 SD cutoff).
The overall permutation P value increased to 0.033 when
only 13 outliers were excluded (using a 5 SD cutoff), and
increased further to 0.10 (non-significant) when no out-
liers were excluded. Using other estimates of GFR, the
associations were slightly less significant. For square-root
transformed CG, P = 0.0007, 0.0018, 0.0079, 0.0046 and
0.0103 for the same top five SNPs, and P = 0.018 overall
(i.e. corrected for multiple testing). For log transformed
creatinine, P = 0.0009, 0.0010, 0.0060, 0.0069 and
0.0073 for the top five SNPs and P = 0.017 overall.
To explore the possibility that SNPs not genotyped on the
Affymetrix 500 K chip might be associated with GFR, we
repeated our analyses using imputed SNP genotypes over
a 400 kb region surrounding ABCB1. Results both with
Table 2: Renal haemodynamics by genotypes for each ABCB1 variant in the Seychelles
2677 G>T 3435 C>T
GG GT TT CC CT TT
N 191 84 15 132 118 40
GFRa (mL/min) 110 ± 32 126 ± 35 128 ± 29b 110 ± 29 118 ± 37 128 ± 31c
GFRa (mL/min/1.73 m2) 103 ± 25 114 ± 26 118 ± 26b 104 ± 24 107 ± 27 117 ± 25c
ERPFd (mL/min) 440 ± 143 488 ± 126 542 ± 109b 434 ± 128 470 ± 150 513 ± 129b
ERPFd (mL/min/1.73 m2) 412 ± 119 445 ± 100 500 ± 102b 413 ± 112 426 ± 117 470 ± 108c
RVRe (mm Hg/min/mL) 0.16 ± 0.06 0.13 ± 0.04 0.12 ± 0.04b 0.16 ± 0.06 0.15 ± 0.06 0.13 ± 0.04c
RVRe (mm Hg/min/mL/1.73 m2) 0.15 ± 0.07 0.13 ± 0.04 0.11 ± 0.05b 0.15 ± 0.07 0.14 ± 0.06 0.12 ± 0.04c
Results are the unadjusted mean ± s.d. aGFR: glomerular filtration rate (inulin clearance). b P < 0.01, c 0.01 <P < 0.05, for linear trend across 
genotypes coded as 0 (GG or CC), 1 (GT or CT) and 2 (TT). dERPF: effective renal plasma flow (PAH clearance). eRVR: renal vascular resistance.
Table 3: Association between the 2677T and 3435T ABCB1 alleles and renal haemodynamics in the Seychelles.
Dependent variable
GFR (mL/min) ERPF (mL/min) RVR (mm Hg/mL/min)
Allele Model Coeff SE P value Coeff SE P value Coeff SE P value
2677T Model 1 9.8 3.5 0.005 37.7 14.3 0.008 -0.015 0.005 0.003
Model 2 10.6 2.9 0.0002 47.5 11.6 0.00004 -0.016 0.004 0.0002
3435T Model 1 6.1 2.7 0.03 29.5 11.4 0.009 -0.011 0.004 0.006
Model 2 4.4 2.3 0.06 28.1 10.5 0.007 -0.011 0.004 0.004
Coeff: regression coefficient. SE: standard error. This table presents 3 * 4 different models, 4 for each dependent variable. Models 1 have age and 
sex as covariates, in addition to either the 2677T or the 3435T allele. Models 2 have age, sex, mean arterial blood pressure, diabetes mellitus, fasting 
blood glucose, body mass index, 24-h urine Na and K excretion (in mmol/24-h) as covariates. An additive mode of action was used for the T allele. 
All models are adjusted for ascertainment. Mean arterial pressure was not added as a covariate for RVR models.Page 5 of 11
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Renal haemodynamics by genotypes for each ABCB1 variantFigure 1
Renal haemodynamics by genotypes for each ABCB1 variant. Bar heights are means and vertical lines standard errors. 
P: P value for linear trend across genotypes using the ASSOC program in S.A.G.E. in models without additional covariates. 
GFR: glomerular filtration rate measured using inulin clearance. ERPF: effective renal plasma flow measured using PAH clear-
ance. RVR: renal vascular resistance.
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Renal haemodynamics by hypertension status for the 2677 C>T ABCB1 variantsFigure 2
Renal haemodynamics by hypertension status for the 2677 C>T ABCB1 variants. Bar heights are means and vertical 
lines standard errors. P: P value for linear trend across genotypes using the ASSOC program in S.A.G.E. in models without 
additional covariates. GFR: glomerular filtration rate measured using inulin clearance. ERPF: effective renal plasma flow meas-
ured using PAH clearance. RVR: renal vascular resistance.
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Figure 3. Three non-coding SNPs, including our top two
hits listed above, showed strong associations (P < 0.001)
[see Additional file 2].
In analyses restricted to 2224 individuals not taking any
prescription drugs (excluding 3 outlying individuals at a 5
SD cutoff), 5 SNPs had permutation P values less than
0.05, and the overall permutation P value corrected for
Genetic associations with GFR, in the region around the ABCB1 geneFigure 3
Genetic associations with GFR, in the region around the ABCB1 gene. Associations are shown for both directly gen-
otyped and imputed SNPs. The bottom panel shows the pattern of linkage disequilibrium in the HapMap CEU panel. We 
imputed genotypes for all HapMap SNPs in the region around ABCB1. In this region, linkage disequilibrium patterns in CoLaus 
were similar to the ones observed in HapMap, although they were resolved at a coarser scale due to lower SNP density. Since 
it was not computationally feasible to combine imputation and permutation approaches, we plot P values calculated assuming 
the normal linear model. For directly genotyped SNPs, the differences between calculated and permutation P values were 
small. The top three hits (and P values) are rs17327624 (0.0006), rs4148733 (0.0008) and rs17327442 (0.0008). The former 
two were directly genotyped and are in strong LD (D' = 0.96 in CoLaus and 1.00 in HapMap CEU, r2 = 0.63 and 0.72 respec-
tively), and the imputed SNP rs17327442 is in perfect LD with rs17327624 in HapMap CEU.Page 8 of 11
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power in this smaller sample size, we conclude that a sim-
ilar association is observed in untreated subjects.
Discussion
In the Seychelles' sample, we measured renal function
using the accepted gold standard, inulin clearance, and
found that ABCB1 genetic variants are associated with the
haemodynamic profile, i.e. GFR, ERPF and RVR in these
individuals of African descent with a positive family his-
tory of hypertension. We confirmed this association of the
ABCB1 gene with renal function, estimated using the sim-
plified MDRD equation, in a large population-based
study of Caucasian subjects. This is, to our knowledge, the
first time that the ABCB1 gene has been shown to be asso-
ciated with renal function in the general population.
As this is not a true replication study (i.e. different ABCB1
marker variants were found to be associated with renal
function in the two populations), these results are prelim-
inary and need to be confirmed in other studies. This may
result from the fact that the Seychelles and Swiss popula-
tions have different ethnic backgrounds and different
linkage disequilibrium structures. In addition, the Sey-
chelles sample was enriched in hypertensive individuals,
whereas the Swiss one was not, which may further explain
differences in findings between the two populations. We
corrected our models for ascertainment (i.e. for the fact
that recruitment was constrained to include two hyperten-
sive siblings in each family). Such a correction aims to
determine what the results would have been had the par-
ticipants not been ascertained this way. This correction
results in better generalizability of our observations.
In the African sample, (1) analyses restricted to subjects
with at least 3 grand-parents of African descent led to very
similar results; and (2) we confirmed the association with
GFR estimated using MDRD in an analysis that included
119 additional African subjects. These results are thus
unlikely to be due to population stratification. The confir-
mation of an association in the Caucasian sample with
variants in the same gene adds further evidence against a
spurious association.
The frequency of the 2677T allele typically varies between
0–10% in subjects of African descent, 39–46% in Cauca-
sians and 36–44% in Asians [24], whereas the frequency
of the 3435T allele typically varies between 16–27% in
subjects of African descent, 48–57% in Caucasians, and
41–66% in Asians. [25] Of note, the frequencies of the
2677T (31%) and 3435T (54%) alleles in our sample are
higher than those reported in other groups of African
descent. The Seychelles' population is a relatively young
population (the islands were first inhabited at the end of
the 18th century) of small size (currently 84,000 inhabit-
ants) that has undergone a population bottleneck during
the middle of the 19th century followed by rapid growth
(census data). Genetic drift may explain why the allele fre-
quency differs in Seychelles versus other African popula-
tions (in Africa or elsewhere). It is not clear to what extent
our observations may reflect the facts that homozygosity
at the 3435T allele is a marker of African descent and Afri-
can ethnicity is a risk factor for developing chronic kidney
disease. Given the large interethnic differences in allele
frequencies observed for ABCB1 variants, it is important
that the associations of ABCB1 variants with renal func-
tion are explored further in other ethnic groups.
The TT genotype of the C3435T polymorphism is associ-
ated with a significant reduction in PGP expression in var-
ious cell types, including renal proximal tubular cells. [26-
29] Although synonymous (i.e. not leading to an amino-
acid change in PGP), the 3435 C>T variant influences
mRNA expression by acting on its stability [30] and on the
substrate specificity of PGP [31]. The 2677 G>T variant is
functional and leads to an Ala893Ser amino acid change
in PGP. The 3435 C>T and 2677 G>T polymorphisms are
in strong linkage disequilibrium. The fact that the 2677
G>T and 3435 C>T ABCB1 variants (and markers in strong
linkage disequilibrium with these variants) were not asso-
ciated with estimated GFR in the CoLaus study suggests
that the true causal variant(s) is (are) in linkage disequi-
librium with the variants genotyped in the Seychelles
sample or that the two populations differ in either modi-
fier genes or environmental components (e.g. the Bal-
kanic toxin [32,33]) affecting the impact of the causal
variant. Further studies are needed to clarify how ABCB1
genetic variants are associated with renal function.
The association reported here between the ABCB1 gene
and renal haemodynamics does not necessarily mean a
causal relationship. However, several independent lines
of evidence of an association with renal function
strengthen our confidence that these results are not spuri-
ous. First, several experimental findings in vitro and in vivo
[5,8,9] and findings in humans [11,12] suggest that either
PGP itself and/or ABCB1 genetic variants play a role in
post-transplantation nephrotoxicity induced by cal-
cineurin inhibitors, such as ciclosporine. Although incon-
sistent (i.e. the T allele is associated with nephrotoxicity in
one study, but with nephroprotection in the other), these
findings nevertheless suggest that PGP influences renal
function via exogenous substances. Hence PGP may influ-
ence renal function via the control of intracellular concen-
tration of a known toxin in the tubular epithelial cells. By
analogy, we put could speculate that PGP influences renal
function via the control of intracellular concentration of
endogenous substances, by an as yet unknown mecha-
nism. Second, Atanasova et al [32] found the ABCB1 hap-
lotype 2677G/3435T to be protective against BalkanPage 9 of 11
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associated with a high incidence of epithelial tumors of
the upper urinary tract. Because of the very specific and
stable geographical localization of this nephropathy, it
has been proposed that an environmental toxin could
play a role in its etiology. [33] However, the familial
aggregation of this nephropathy suggests that genetic fac-
tors are also likely to be involved. [33] Third, endothelins
are important regulators of renal blood flow and glomer-
ular filtration rate [34] that can influence PGP-mediated
transport [35,36]. Bosentan, an endothelin receptor
antagonist, activates the pregnane X receptor [37], which
itself activates ABCB1 expression [38].
Conclusion
In conclusion, we found that selected ABCB1 gene vari-
ants were associated with renal function and haemody-
namics in families of African descent, while other ABCB1
gene variants were associated with GFR estimates (MDRD
and CG) in another study of Caucasian individuals.
Although the associations were not based on the same
markers in the two populations, these results suggest that
variants of the ABCB1 gene influence renal function in the
general population. The ABCB1 gene therefore represents
a new candidate gene for nephropathy in humans. Repli-
cation in additional studies is warranted.
Abbreviations
PGP: P-glycoprotein; GFR: glomerular filtration rate;
ERPF: effective renal plasma flow; MDRD: Modification of
the Diet in Renal Disease; CG: Cockcroft-Gault; RVR:
renal vascular resistance; MAP: Mean arterial blood pres-
sure; BMI; body mass index.
Competing interests
The authors declare that they have no competing interests.
Dawn Waterworth and Vincent Mooser are full-time
employees of GlaxoSmithKline.
Authors' contributions
AG, CBE, DMW, MBu, MM, PB, PV and VM participated to
the conduct and/or design of the studies. MBo, JSB, RCE,
TJ and SB participated in the data analyses. DMW, MBo,
MM, PV, and VM were involved in the data acquisition.
All authors have been involved in drafting the manuscript
or revising it critically for important intellectual content.
All authors have given final approval of the version to be
published.
Additional material
Acknowledgements
We are indebted to all study participants. Parts of the results have been 
published in abstract format at the ASN's 39th 2006 Annual Meeting, San 
Diego, California. The computations were performed in part at the Vital-
IT. Center for high-performance computing of the Swiss Institute of Bioin-
formatics. We thank the Ministry of Health of the Republic of Seychelles for 
their support of this epidemiological research; Air Seychelles and SkyChef 
for their logistic support in transporting material, Norma Both and Gylian 
Mein for data collection. The Seychelles study benefited from a grant from 
the Swiss National Science Foundation (TANDEM No 31-51115.97). M. 
Bochud is supported by a grant from the Swiss National Science Foundation 
(PROSPER 3200BO-111362/1 and 111361/1) and by the University Insti-
tute of Social and Preventive Medicine in Lausanne. R.C. Elston is supported 
by a U.S. Public Health Service resource grant (1 P41 RR03655) from the 
National Center for Research Resources and research grant (GM28356) 
from the National Institute of General Medical Sciences. S. Bergmann is 
supported by the Giorgi-Cavaglieri Foundation and the Swiss National Sci-
ence Foundation (Grant # 3100AO-116323/1). M. Burnier is supported by 
the Swiss National Science Foundation (Project No 3100A0-103629). The 
CoLaus Study was supported by research grants from GlaxoSmithKline and 
from the Faculty of Biology and Medicine of Lausanne, Switzerland. The 
authors would like to express their gratitude to Yolande Barreau, Anne-
Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy 
Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection, and to 
Gérard Waeber, Fred Paccaud, Allen Roses, and Lefkos T. Middleton for 
their support.
References
1. Meguid El NA, Bello AK: Chronic kidney disease: the global
challenge.  Lancet 2005, 365:331-340.
2. Bochud M, Elston RC, Maillard M, Bovet P, Schild L, Burnier M: Her-
itability of renal function in hypertensive families of African
descent in the Seychelles (Indian Ocean).  Kidney Int 2005,
67:61-69.
3. Lei HH, Perneger TV, Klag MJ, Whelton PK, Coresh J: Familial
aggregation of renal disease in a population-based case-con-
trol study.  J Am Soc Nephrol 1998, 9:1270-1276.
4. Langefeld CD, Beck SR, Bowden DW, Rich SS, Wagenknecht LE,
Freedman BI: Heritability of GFR and albuminuria in Cauca-
sians with type 2 diabetes mellitus.  Am J Kidney Dis 2004,
43:796-800.
Additional file 1
Additional information on methods. The data provided represent addi-
tional information on phenotype and covariate measurements in the Sey-
chelles study and statistical analyses in the CoLaus study
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8794-1-21-S1.doc]
Additional file 2
Association of ABCB1 SNPs with square-root transformed MDRD in 
CoLaus. The data provided represent association data of genotyped and 
imputed SNPs located within and around the ABCB1 gene with square-
root transformed MDRD in CoLaus.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8794-1-21-S2.pdf]Page 10 of 11
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:21 http://www.biomedcentral.com/1755-8794/1/215. Hauser IA, Koziolek M, Hopfer U, Thevenod F: Therapeutic con-
centrations of cyclosporine A, but not FK506, increase P-
glycoprotein expression in endothelial and renal tubule cells.
Kidney Int 1998, 54:1139-1149.
6. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willing-
ham MC: Cellular localization of the multidrug-resistance
gene product P-glycoprotein in normal human tissues.  Proc
Nat Acad Sci U S A 1987, 84:7735-7738.
7. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN: Expression of
MDR1 (multidrug resistance) gene and its protein in normal
human kidney.  Nephron 1997, 77:284-289.
8. Del Moral RG, Olmo A, Osuna A, Aguilar M, Carvia R, Becerra P,
Arrebola F, Guillen M, Reguero ME, Asensio C, O'Valle F: Role of P-
glycoprotein in chronic cyclosporine nephrotoxicity and its
relationship to intrarenal angiotensin II deposits.  Transplant
Proc 1998, 30:2014-2016.
9. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA: Expression
of multidrug resistance P-glycoprotein in kidney allografts
from cyclosporine A-treated patients.  Kidney Int 2001,
60:156-166.
10. Foote CJ, Greer W, Kiberd BA, Fraser A, Lawen J, Nashan B, Belitsky
P: MDR1 C3435T polymorphisms correlate with
cyclosporine levels in de novo renal recipients.  Transplant Proc
2006, 38:2847-2849.
11. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Goss-
mann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H,
Eichelbaum M, Schwab M: ABCB1 genotype of the donor but
not of the recipient is a major risk factor for cyclosporine-
related nephrotoxicity after renal transplantation.  J Am Soc
Nephrol 2005, 16:1501-1511.
12. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis
CL, Marsh CL, Schuetz EG, Thummel KE: Association between
ABCB1 (multidrug resistance transporter) genotype and
post-liver transplantation renal dysfunction in patients
receiving calcineurin inhibitors.  Pharmacogenetics 2003,
13:661-674.
13. Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE: MDR1 geno-
type-dependent regulation of the aldosterone system in
humans.  Pharmacogenet Genomics 2007, 17:137-144.
14. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ,
Perrone RD, Lau J, Eknoyan G: National Kidney Foundation
Practice Guidelines for Chronic Kidney Disease: Evaluation,
Classification, and Stratification.  Ann Intern Med 2003,
139:137-147.
15. DuBois M, DuBois EF: A formula to estimate the approximate
surface area if height and weight be known.  Arch Intern Med
1916, 17:863-871.
16. Eap CB, Fellay J, Buclin T, Bleiber G, Golay KP, Brocard M, Baumann
P, Telenti A: CYP3A activity measured by the midazolam test
is not related to 3435 C>T polymorphism in the multiple
drug resistance transporter gene.  Pharmacogenetics 2004,
14:255-260.
17. Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L, Shamlaye
C, Burnier M: Association of CYP3A5 genotypes with blood
pressure and renal function in African families.  J Hypertens
2006, 24:923-929.
18. S.A.G.E. (Statistical Analysis for Genetic Epidemiology) ver-
sion 5.3  2006 [http://darwin.cwru.edu/sage/].
19. Bochud M, Bovet P, Elston RC, Paccaud F, Falconnet C, Shamlaye C,
Burnier M: High heritability of ambulatory blood pressure in
families of East African descent.  Hypertension 2005, 45:445-450.
20. Zhang K, Sun F, Zhao H: HAPLORE: a program for haplotype
reconstruction in general pedigrees without recombination.
Bioinformatics 2005, 21:90-103.
21. Cockcroft DW, Gault MH: Prediction of creatinine clearance
from serum creatinine.  Nephron 1976, 16:31-41.
22. Team RDC: R Development Core Team. R: A language and
environment for statistical computing. R Foundation for Sta-
tistical Computing,.  2007 [http://www.R-project.org]. Vienna,
Austria
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender
D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool
set for whole-genome association and population-based link-
age analyses.  Am J Hum Genet 2007, 81:559-575.
24. Kurzawski M, Pawlik A, Gornik W, Drozdzik M: Frequency of com-
mon MDR1 gene variants in a Polish population.  Pharmacol
Rep 2006, 58:35-40.
25. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton
N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA,
McLeod HL: MDR1 pharmacogenetics: frequency of the
C3435T mutation in exon 26 is significantly influenced by
ethnicity.  Pharmacogenetics 2001, 11:217-221.
26. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J,
Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U:
Functional polymorphisms of the human multidrug-resist-
ance gene: Multiple sequence variations and correlation of
one allele with P-glycoprotein expression and activity in vivo.
Proc Nat Acad Sci U S A 2000, 97:3473-3478.
27. Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, Khoo
SH: Functional Correlation of P-Glycoprotein Expression and
Genotype with Expression of the Human Immunodeficiency
Virus Type 1 Coreceptor CXCR4.  J Virol 2004, 78:12022-12029.
28. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP,
Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L,
Schinkel AH, Vernazza P, Eap CB, Telenti A: Response to antiret-
roviral treatment in HIV-1-infected individuals with allelic
variants of the multidrug resistance transporter 1: a phar-
macogenetics study.  Lancet 2002, 359:30-36.
29. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M,
Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U,
Kerb R, Hoffmeyer S, Brauch H: ASSociation of the P-Glycopro-
tein Transporter MDR1 C3435T Polymorphism with the
Susceptibility to Renal Epithelial Tumors.  J Am Soc Nephrol
2002, 13:1847-1854.
30. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug
resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T
affects mRNA stability.  Pharmacogenet Genomics 2005,
15:693-704.
31. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambud-
kar SV, Gottesman MM: A "silent" polymorphism in the MDR1
gene changes substrate specificity.  Science 2007, 315:525-528.
32. Atanasova S, von Ahsen N, Dimitrov T, Armstrong V, Oellerich M,
Toncheva D: MDR1 haplotypes modify BEN disease risk: a
study in Bulgarian patients with Balkan endemic nephropa-
thy compared to healthy controls.  Nephron Physiol 2004,
96:e7-13.
33. Toncheva D, Dimitrov T, Stojanova S: Etiology of Balkan endemic
nephropathy: a multifactorial disease?  Eur J Epidemiol 1998,
14:389-394.
34. Neuhofer W, Pittrow D: Role of endothelin and endothelin
receptor antagonists in renal disease.  Eur J Clin Invest 2006, 36
Suppl 3:78-88.
35. Masereeuw R, Terlouw SA, van Aubel RA, Russel FG, Miller DS:
Endothelin B receptor-mediated regulation of ATP-driven
drug secretion in renal proximal tubule.  Mol Pharmacol 2000,
57:59-67.
36. Terlouw SA, Masereeuw R, Russel FG, Miller DS: Nephrotoxicants
induce endothelin release and signaling in renal proximal
tubules: effect on drug efflux.  Mol Pharmacol 2001, 59:1433-1440.
37. van Giersbergen PLM, Gnerre C, Treiber A, Dingemanse J, Meyer
UA: Bosentan, a dual endothelin receptor antagonist, acti-
vates the pregnane X nuclear receptor.  European Journal of
Pharmacology 2002, 450:115-121.
38. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hira-
matsu Y: The Pregnane X Receptor Regulates Gene Expres-
sion in a Ligand- and Promoter- Selective Fashion.  Mol
Endocrinol 2005, 19:1170-1180.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1755-8794/1/21/prepubPage 11 of 11
(page number not for citation purposes)
